Form 8-K - Current report:
SEC Accession No. 0001193125-25-100433
Filing Date
2025-04-28
Accepted
2025-04-28 16:02:27
Documents
14
Period of Report
2025-04-22
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d807820d8k.htm   iXBRL 8-K 35797
2 EX-99.1 d807820dex991.htm EX-99.1 8769
  Complete submission text file 0001193125-25-100433.txt   174168

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA spro-20250422.xsd EX-101.SCH 2869
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE spro-20250422_lab.xml EX-101.LAB 17995
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE spro-20250422_pre.xml EX-101.PRE 11274
16 EXTRACTED XBRL INSTANCE DOCUMENT d807820d8k_htm.xml XML 3635
Mailing Address 675 MASSACHUSETTS AVENUE 14TH FLOOR CAMBRIDGE MA 02139
Business Address 675 MASSACHUSETTS AVENUE 14TH FLOOR CAMBRIDGE MA 02139 857-242-1600
Spero Therapeutics, Inc. (Filer) CIK: 0001701108 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38266 | Film No.: 25880155
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)